Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Wall Street Analyst Weigh In
Separately, Craig Hallum initiated coverage on shares of Xeris Biopharma in a report on Thursday, April 28th. They set a "buy" rating and a $6.50 price objective on the stock.
Xeris Biopharma Price Performance
Shares of Xeris Biopharma stock opened at $1.67 on Monday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 2.42 and a current ratio of 2.67. The firm's 50-day simple moving average is $1.69 and its 200-day simple moving average is $2.13. Xeris Biopharma has a twelve month low of $1.25 and a twelve month high of $3.17. The firm has a market cap of $226.34 million and a P/E ratio of -1.14.
Xeris Biopharma (NASDAQ:XERS - Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Xeris Biopharma had a negative net margin of 217.81% and a negative return on equity of 258.57%. The business had revenue of $22.07 million for the quarter, compared to analyst estimates of $22.92 million. As a group, research analysts expect that Xeris Biopharma will post -0.83 EPS for the current fiscal year.
Insider Transactions at Xeris Biopharma
In other Xeris Biopharma news, insider Paul R. Edick purchased 100,000 shares of the company's stock in a transaction that occurred on Thursday, May 12th. The stock was acquired at an average cost of $1.40 per share, with a total value of $140,000.00. Following the completion of the purchase, the insider now directly owns 1,508,064 shares in the company, valued at approximately $2,111,289.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.17% of the stock is owned by company insiders.